Poxel SA

Poxel SAis a lyonbiopole member

General information

259/261 avenue Jean Jaurès

69007 Lyon

Incorporated in: 2009/03/11

Number of employees: 23

More information


Main activity

Created in 2009 as a spin out of Merck Serono, Poxel is a dynamic biopharmaceutical company that uses its extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. Imeglimin, Poxel’s first-in-class lead drug candidate targeting mitochondrial dysfunction. Together, with its partner Sumitomo Dainippon Pharma, Poxel is conducting the Phase 3 TIMES program of Imeglimin for the treatment of type 2 diabetes in Japan. Poxel also established a partnership with Roivant Sciences for Imeglimin’s development and commercialization in countries outside of the partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, Poxel's first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, entered a Phase 2a proof-of-concept program for the treatment of NASH in early April 2019 with results expected in the second quarter of 2020. PXL065, Poxel’s mitochondrial pyruvate carrier (MPC) inhibitor, entered a Phase 1b multiple ascending dose trial in September 2019 and this Phase 1 NASH program is expected to be completed in the fourth quarter of 2019.


Looking for funding: Yes

Private funding obtained: €34m from Edmond de Rothschild Investment Partners,Bpi France and Omnes Capital (ex-Credit Agricole Private Equity)

Public funding obtained: Sept. 2009: €215,000 grant from FEDER and €250,000 grant from Le Grand Lyon for  NATHEB project. Oct. 2011: €1.45m from OSEO

Stock exchange listing: Listed on Euronext on February 6, 2015: €26;8 M raised

Products / Services / Technologies
Partnership opportunities / Licensing

Strategic area of application
Human Medicine

Application market
Metabolic Diseases

Therapeutics, Pharma or Biotech


By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree